Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Drug Safety and Availability

Drug Safety and Availability

                        Drug Alerts and Statements
          Information about Nitrosamine Impurities in Medications
          Medication Guides
          Drug Safety Communications


                        Food and Drug Administration Overdose Prevention Framework
          Drug Shortages
          FDA Drug Safety Podcasts
          Information by Drug Class
          Medication Errors Related to CDER-Regulated Drug Products
          Postmarket Drug Safety Information for Patients and Providers
          Risk Evaluation and Mitigation Strategies | REMS
          Safe Use Initiative
          Drug Recalls
          Drug Supply Chain Integrity
          Multistate outbreak of fungal meningitis and other infections Home
          Drugs
          Drug Safety and Availability
          FDA revises letter of authorization for the emergency use authorization for PaxlovidDrug Safety and Availability FDA revises letter of authorization for the emergency use authorization for Paxlovid
  
  	
    Share
    Post
    Linkedin

    Email
    Print**[01/29/2024]** In December 2021, FDA authorized Paxlovid for emergency use for the treatment of adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. In May 2023, FDA approved Pfizer’s new drug application (NDA) for Paxlovid for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

**Today, FDA is announcing a revision to the Paxlovid emergency use authorization (EUA), stating that Paxlovid manufactured and labeled in accordance with the EUA (EUA-labeled Paxlovid) currently in U.S. distribution will remain authorized for use through the labeled or extended expiration date, as applicable, or through March 8, 2024, whichever is earlier.**

EUA-labeled Paxlovid will no longer be authorized for emergency use after March 8, 2024, regardless of the labeled or extended expiration date. However, the Paxlovid EUA will continue to authorize emergency use of Paxlovid manufactured and labeled in accordance with the NDA (NDA-labeled Paxlovid) for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death.

This revision to the Paxlovid EUA is the next phase in the transition from the use of EUA-labeled Paxlovid to the use of NDA-labeled Paxlovid. This transition began on November 1, 2023, with the introduction of FDA-approved Paxlovid (NDA-labeled Paxlovid).1,2

To ensure ongoing availability of Paxlovid at the point of dispensing and to facilitate a smooth transition to FDA-approved Paxlovid (NDA-labeled Paxlovid), we are providing information in the revised authorization on the timing of the shift from the use of EUA-labeled Paxlovid to NDA-labeled Paxlovid so that dispensing sites (e.g., pharmacies) that have not yet transitioned to NDA-labeled Paxlovid have time to do so.

**Impact on Pharmacies, Pharmacists, and Other Health Care Providers**

Through March 8, 2024, unexpired EUA-labeled Paxlovid can be dispensed to patients when consistent with the terms and conditions of the EUA. See the Frequently Asked Questions on the Emergency Use Authorization for Paxlovid for Treatment of COVID-19 for additional information related to the dispensing of Paxlovid.

Both providers and patients should visit Pfizer’s website for information on lots of EUA-labeled Paxlovid that are the subject of a shelf-life extension. Lots of EUA-labeled Paxlovid not listed on Pfizer’s website may only be used through the labeled expiration date, or through March 8, 2024, whichever is earlier.

Expired EUA-labeled Paxlovid must be returned to the manufacturer or disposed of in accordance with all federal, state, and local regulations. Similarly, after March 8, 2024, all EUA-labeled Paxlovid remaining in U.S. distribution must also be returned to the manufacturer or disposed of in accordance with all federal, state, and local regulations.

**Impact on Patients**

Patients who have a prescription for Paxlovid will continue to receive either EUA-labeled or NDA-labeled Paxlovid through March 8, 2024. After that date, they will receive NDA-labeled Paxlovid. More information about Paxlovid, including the differences in packaging between EUA-labeled and NDA-labeled Paxlovid, is available at FDA’s frequently asked questions and answers.

Patients who receive a prescription of EUA-labeled Paxlovid on or prior to March 8, 2024, and have initiated treatment on or prior to that date, may complete their course of treatment even if completion of treatment were to occur after March 8, 2024. If patients have a question about the expiration date on the box of Paxlovid they have received, they should talk with their pharmacist and can also check Pfizer’s website for updated expiration dates.

Through December 31, 2024, eligible patients qualify for free Paxlovid through the PAXCESS program. Eligible patients include Medicare beneficiaries, Medicaid beneficiaries, and uninsured individuals who do not have a prescription drug benefit at the time they fill their prescription. Patients who are commercially insured may be eligible for assistance though a co-pay savings program.

**Additional Resources**

Letter of Authorization for EUA Paxlovid
	FDA’s Frequently Asked Questions on the Emergency Use Authorization for Paxlovid for Treatment of COVID-19
	Health and Human Services Guidance on Sunsetting of the US Government’s COVID-19 Therapeutics Distribution Program.
	Paxlovid landing page at Health and Human Services’ Administration for Strategic Preparedness & Response.
	To review information about the commercial availability of Paxlovid, read Pfizer’s statement.
	For questions on how to obtain approved Paxlovid, please visit Pfizer’s Paxlovid page.1 FDA Roundup: November 3, 2023: https://www.fda.gov/news-events/press-announcements/fda-roundup-november-3-2023

2 Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program: https://aspr.hhs.gov/COVID-19/Therapeutics/Pages/COVID19-Tx-Transition-Guide.aspx

                                                                                  Content current as of:
      01/29/2024
              
              
Regulated Product(s)
		 DrugsDrug Safety and Availability

          
                        Drug Alerts and Statements
          Information about Nitrosamine Impurities in Medications
          Medication Guides
          Drug Safety Communications


                        Food and Drug Administration Overdose Prevention Framework
          Drug Shortages
          FDA Drug Safety Podcasts
          Information by Drug Class
          Medication Errors Related to CDER-Regulated Drug Products
          Postmarket Drug Safety Information for Patients and Providers
          Risk Evaluation and Mitigation Strategies | REMS
          Safe Use Initiative
          Drug Recalls
          Drug Supply Chain Integrity
          Multistate outbreak of fungal meningitis and other infections
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop